business

Celcuity Crashes On Breast Cancer Disappointment; What Happened?

Yahoo Finance · Jun 2, 2026, 1:24 PM · Also reported by 3 other sources

Celcuity (CELC) stock crashed Tuesday after the company said its three-drug regimen doubled the likelihood of survival without progression for patients with an advanced form of breast cancer. Patients lived for a median of 11.1 months without worsening after being treated with three drugs: Celcuity's gedatolisib combined with fulvestrant and palbociclib. In comparison, those given the fulvestrant and another drug…

Article preview — originally published by Yahoo Finance. Full story at the source.

Read full story on Yahoo Finance → More top stories

Also covered by

Healthline GLP-1 Drugs May Improve Breast Cancer Survival, Lower Risk of Recurrence Healthline New Breast Density Treatment May Have Fewer Side Effects, Lower Cancer Risk Healthline Real Housewives Star Says Breast Cancer Gave Her a ‘Different Type of Strength’

Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop

Celcuity Crashes On Breast Cancer Disappointment; What Happened?

Also covered by

More in business